3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 3
1
Status
Unknown
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Carcinoma, Non-Small-Cell Lung
3
Whole-Brain Radiotherapy
1
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Squamous Non-small Cell Lung Cancer
1
Small Cell Lung Carcinoma
1
Sarcoma, Synovial
1
Sarcoma, Alveolar Soft Part
1
Sarcoma
1
Ovarian Neoplasms
1
Nasopharyngeal Carcinoma
1
Lung Neoplasms
1
Leiomyosarcoma
1
Fallopian Tube Neoplasms
1
Extensive Small Cell Lung Cancer
1
Endometrial Neoplasms
1
Carcinoma, Hepatocellular
1
Advanced Renal Cancer
1
Advanced Non-small Cell Lung Cancer
1
Interventions
Paclitaxel
45
Carboplatin
33
Bevacizumab
17
liposomal doxorubicin
15
Topotecan
12
Taxes
10
Gemcitabine
10
Drug Therapy
6
Cisplatin
6
rucaparib
5
mirvetuximab soravtansine
5
Docetaxel
5
Immunoglobulin G
4
Doxorubicin
4
Disulfides
4
trebananib
3
pembrolizumab
3
olaparib
3
Saline Solution
3
Neoadjuvant Therapy
3
Hyperthermic Intraperitoneal Chemotherapy
3
Dexamethasone
3
CP protocol
3
niraparib
2
cediranib
2
Tamoxifen
2
Specimen Handling
2
Letrozole
2
Glucose
2
Cytoreduction Surgical Procedures
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Fallopian Tube Neoplasms
×
anlotinib
×
Clear all
NCT02584478
2023-11-08
AL3818
Advenchen Laboratories, LLC
Phase 3
Unknown
294 enrolled